This page in English

Sara Rundquist

Tjänstetitel: Doktorand Organisation: Institutionen för medicinska vetenskaper

E-post:

Telefon: 019 302181

Rum: C2209

Sara Rundquist

Forskningsämne

Om Sara Rundquist

Sara arbetar för närvarande som ST-läkare på gastrosektionen vid Medicinska kliniken på Universitetssjukhuset i Örebro. Hon är även registrerad doktorand vid Örebro Universitet sedan 2017. Det övergripande syftet med avhandlingen är att öka kunskapen om behandling vid inflammatorisk tarmsjukdom genom att kartlägga effekten och komplikationer av olika behandlingsalternativ.  För fullständig beskrivning, var god se den engelska versionen av denna sida.

Publikationer

Artiklar i tidskrifter |  Konferensbidrag | 

Artiklar i tidskrifter

Rundquist, S. , Sachs, M. C. , Eriksson, C. , Olén, O. , Montgomery, S. & Halfvarson, J. (2021). Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers. Alimentary Pharmacology and Therapeutics (4), 471-483.
Rundquist, S. , Sachs, M. C. , Eriksson, C. , Olén, O. , Montgomery, S. & Halfvarson, J. (2021). Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply. Alimentary Pharmacology and Therapeutics, 53 (5), 642-643.
Rundquist, S. , Sachs, M. C. , Eriksson, C. , Olén, O. , Montgomery, S. & Halfvarson, J. (2021). Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply. Alimentary Pharmacology and Therapeutics, 53 (9), 1046-1047.
Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Udumyan, R. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. & et al. (2021). Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. Therapeutic Advances in Gastroenterology, 14.
Rundquist, S. , Sachs, M. , Eriksson, C. , Olén, O. , Montgomery, S. & Halfvarson, J. (2020). Effectiveness of anti-TNF vs. vedolizumab as a second biologic in IBD: results from national Swedish registers. Journal of Crohn's & Colitis, 14 (Suppl. 1), S317-S318.
Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Udumyan, R. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. & et al. (2020). Real-world effectiveness of vedolizumab in ulcerative colitis: Week 52 results from the Swedish multi-centre, prospective, observational SVEAH UC study. Journal of Crohn's & Colitis, 14 (Suppl. 1), S576-S577.
Eriksson, C. , Rundquist, S. , Cao, Y. , Montgomery, S. & Halfvarson, J. (2019). Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study. Gut, 68 (4), 623-632.
Rundquist, S. , Eriksson, C. , Nilsson, L. , Angelison, L. , Jäghult, S. , Björk, J. , Grip, O. , Hjortswang, H. & et al. (2018). Clinical effectiveness of golimumab in Crohn's disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scandinavian Journal of Gastroenterology, 53 (10-11), 1257-1263.
Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Karlen, P. , Grip, O. , Söderman, C. , Almer, S. , Hertervig, E. & et al. (2018). Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn's disease (SVEAH CD). Journal of Crohn's & Colitis, 12 (Suppl. 1), S494-S495.
Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Karlen, P. , Grip, O. , Söderman, C. , Almer, S. , Hertervig, E. & et al. (2018). Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC). Journal of Crohn's & Colitis, 12 (Suppl. 1), S382-S383.
Eriksson, C. , Rundquist, S. , Cao, Y. , Montgomery, S. & Halfvarson, J. (2018). The impact of thiopurine drugs on the natural history and surgical outcome of ulcerative colitis: A cohort study. Journal of Crohn's & Colitis, 12 (Suppl. 1), S481-S481.
Eriksson, C. , Rundquist, S. , Lykiardopoulos, B. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. , Hertervig, E. & et al. (2017). A Swedish observational study (SVEAH) on vedolizumab assessing effectiveness and healthcare resource utilization in patients with inflammatory bowel disease. Journal of Crohn's & Colitis, 11 (Suppl. 1), S262-S263.
Eriksson, C. , Cao, Y. , Rundquist, S. , Zhulina, Y. , Henriksson, I. , Montgomery, S. & Halfvarson, J. (2017). Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Orebro, Sweden, 1963-2010. Alimentary Pharmacology and Therapeutics, 46 (8), 748-757.
Eriksson, C. , Cao, Y. , Rundquist, S. , Zhulina, Y. , Henriksson, I. , Montgomery, S. & Halfvarson, J. (2017). Editorial: do thiopurines and biologics decrease the risk of colectomy? Authors' reply. Alimentary Pharmacology and Therapeutics, 46 (9), 897-898.

Konferensbidrag

Rundquist, S. , Eriksson, C. , Nilsson, L. , Angelison, L. , Jäghult, S. , Björk, J. , Grip, O. , Hjortswang, H. & et al. (2018). Clinical effectiveness of golimumab in Crohn´s disease – an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Konferensbidrag vid 26th United European Gastroenterology Week, Vienna, Austria, October 20-24, 2018.